CoChat

Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling

Open access
Liu, Lu, Ammar, David A., Ross, Lindsey A., Mandava, Naresh, Kahook, Malik Y., Carpenter, John F. · 2011 · Investigative Opthalmology & Visual Science

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

PURPOSE: To quantify levels of subvisible particles and protein aggregates in repackaged bevacizumab obtained from compounding pharmacies, as well as in samples of bevacizumab and ranibizumab tested in controlled laboratory experiments. METHODS: Repackaged bevacizumab was purchased from four external compounding pharmacies. For controlled laboratory studies, bevacizumab and placebo were drawn into plastic syringes and incubated at -20°C, 4°C, and room temperature (with and without exposure to light) for 12 weeks. In addition, mechanical shock occurring during shipping was mimicked with syringes containing bevacizumab. Particle counts and size distributions were quantified by particle characterization technology. Levels of monomer and soluble aggregates of bevacizumab were determined with size-exclusion high-performance liquid chromatography (SE-HPLC). RESULTS: Repackaged bevacizumab from the compounding pharmacies had a wide range of particle counts (89,006 ± 56,406 to 602,062 ± 18,349/mL). Bevacizumab sampled directly from the original glass vial had particle counts of 63,839 ± 349/mL. There was up to a 10% monomer loss in the repackaged bevacizumab. Laboratory samples of repackaged bevacizumab and placebo had initial particle counts, respectively, of 283,675 ± 60,494/mL and 492,314 ± 389,361/mL. Freeze-thawing of both bevacizumab and placebo samples led to >1.2 million particles/mL. In all repackaged samples, most of the particles were due to silicone oil. SE-HPLC showed no significant differences for repackaged samples incubated in the laboratory under various conditions, compared with bevacizumab directly from vial. However, repeated freeze-thawing caused a more than 10% monomer loss. CONCLUSIONS: Bevacizumab repackaged in plastic syringes could contain protein aggregates and is contaminated by silicone oil microdroplets. Freeze-thawing or other mishandling can further increase levels of particle contaminants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1167/iovs.10-6431

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 2

  1. [15]15. Sharma DK Oma P, Krishnan S. Silicone microdroplets in protein formulations detection and enumeration. Pharm Technol 2009;33: 74-79.
  2. [18]18. Crampton S, Ricci M. Development and Application of a Fourier Transform Infrared (FTIR) Spectroscopy Method to Quantify Silicone Oil Extracted from Syringes. AAPS National BioTechnology. Conference. San Francisco: The American Association of Pharmaceutical Scientists; 2010.

Cited by

See all 206

Metadata

Authors
Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F.
Affiliations
  • University of Colorado Denver (US)
  • University of Colorado Anschutz (US)
  • From the Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and
Venue
Investigative Opthalmology & Visual Science
Published
2011-02-22
Volume
52
Issue
2
Pages
1023
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W2031531075
Cited by
199
References
21
Citations by year
2026: 4 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 10 · 2021: 25 · 2020: 16 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 10 · 2015: 10 · 2014: 15 · 2013: 14 · 2012: 19
FWCI
5.35
Type
journal article
Language
en
Open access
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Biomedical Imaging and Bioengineering (R01EB006006)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
bevacizumab, ranibizumab, compounding pharmacies, protein aggregates, subvisible particles, freeze-thaw cycles, drug storage conditions, plastic syringes
MeSH terms
Bevacizumab, Ranibizumab, Antibodies, Monoclonal, Drug Compounding, Drug Packaging, Drug Stability, Drug Storage, Particle Size, Silicone Oils, Angiogenesis Inhibitors, Particulate Matter, Protein Multimerization, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.